BioCryst Reports Mixed Q1 2026: ORLADEYO Growth Offset by Astria Acquisition Charges
Event summary
- ORLADEYO revenue grew 11% year-over-year to $148.3 million, or 21% excluding European revenue.
- BioCryst licensed European rights for navenibart to Neopharmed Gentili for $70 million upfront and up to $275 million in milestones.
- Q1 2026 GAAP operating loss of $701.6 million due to a $697.8 million non-cash charge from the Astria acquisition.
- Full-year 2026 revenue guidance maintained at $635 million to $660 million.
- Sandeep M. Menon appointed as Chief Research and Development Officer.
The big picture
BioCryst's Q1 2026 results highlight the tension between revenue growth from ORLADEYO and the financial strain of strategic acquisitions. The licensing deal for navenibart in Europe underscores the company's focus on rare disease treatments, but the significant non-cash charge from the Astria acquisition raises questions about its capital efficiency. The biotech sector's emphasis on pipeline development and commercial execution will be key to BioCryst's long-term success.
What we're watching
- Pipeline Progress
- Whether BioCryst can maintain its timeline for navenibart's regulatory filing by the end of 2027.
- Financial Discipline
- How the company will balance its focus on rare diseases with the financial burden of recent acquisitions.
- Commercial Strategy
- The pace at which BioCryst can grow ORLADEYO revenue outside Europe following the licensing deal.
Related topics